Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Perspective Therapeutics (CATX) EBITDA Margin (2016 - 2023)

Perspective Therapeutics' EBITDA Margin history spans 14 years, with the latest figure at 238.19% for Q4 2023.

  • On a quarterly basis, EBITDA Margin changed N/A to 238.19% in Q4 2023 year-over-year; TTM through Dec 2023 was 6678.79%, a N/A change, with the full-year FY2023 number at 2855.02%, changed N/A from a year prior.
  • EBITDA Margin hit 238.19% in Q4 2023 for Perspective Therapeutics, up from 446.22% in the prior quarter.
  • Over the last five years, EBITDA Margin for CATX hit a ceiling of 238.19% in Q4 2023 and a floor of 650.27% in Q2 2023.
  • Historically, EBITDA Margin has averaged 117.36% across 5 years, with a median of 52.17% in 2020.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 10184bps in 2021 and later tumbled -56619bps in 2023.
  • Tracing CATX's EBITDA Margin over 5 years: stood at 40.93% in 2019, then increased by 10bps to 37.01% in 2020, then crashed by -57bps to 58.06% in 2021, then tumbled by -322bps to 245.08% in 2022, then skyrocketed by 197bps to 238.19% in 2023.
  • Business Quant data shows EBITDA Margin for CATX at 238.19% in Q4 2023, 446.22% in Q3 2023, and 650.27% in Q2 2023.